4/11/2011

The FDA is not requiring drugmakers to change usage and safety information for Shire's Adderall XR, Novartis' Ritalin and other stimulants for attention-deficit/hyperactivity disorder. The agency said it will provide an update after it finishes analyzing ADHD drugs' potential risk of cardiovascular events.

Full Story:
Reuters

Related Summaries